Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00062179 2020-08-03

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2 Completed

7 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00520845 2017-03-20

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Phase 2 Terminated

23 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00070486 2016-06-30

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

140 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00030407 2013-04-29

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

Phase 2 Completed

34 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00030420 2013-04-29

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

24 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00068653 2013-04-29

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Phase 2 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00527982 2012-12-06

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

Phase 2 Terminated

1 enrolled 2 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms

NCT00058006 2012-06-11

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Phase 2 Completed

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Salivary Gland Neoplasms

NCT01503385 2012-01-04

Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2 Unknown

100 enrolled

Thoracic

Lung Neoplasms

NCT00055978 2011-06-20

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

Phase 2 Completed

112 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00181532 2009-06-30

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Phase 2 Completed

102 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00274898 2009-02-09

Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer

Phase 2 Unknown

80 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer

Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small Cell Lung Cancer

Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer